SLNSW-First-line nivolumab plus chemotherapy versus che...-TN_cdi_proquest_journals_2547491434

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Full title: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Author/creator: Janjigian, Yelena Y, Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan, Yamaguchi, Kensei, Skoczylas, Tomasz, Campos Bragagnoli, Arinilda, Liu, Tianshu, Schenker, Michael, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V, Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M, Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, Ajani, Jaffer A.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2547491434

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2547491434

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    Record identifier

    TN_cdi_proquest_journals_2547491434

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2547491434

    Share

    First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2547491434

    First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    Full title

    First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    Author / Creator

    Janjigian, Yelena Y ; Shitara, Kohei ; Moehler, Markus ; Garrido, Marcelo ; Salman, Pamela ; Shen, Lin ; Wyrwicz, Lucjan ; Yamaguchi, Kensei ; Skoczylas, Tomasz ; Campos Bragagnoli, Arinilda ; Liu, Tianshu ; Schenker, Michael ; Yanez, Patricio ; Tehfe, Mustapha ; Kowalyszyn, Ruben ; Karamouzis, Michalis V ; Bruges, Ricardo ; Zander, Thomas ; Pazo-Cid, Roberto ; Hitre, Erika ; Feeney, Kynan ; Cleary, James M ; Poulart, Valerie ; Cullen, Dana ; Lei, Ming ; Xiao, Hong ; Kondo, Kaoru ; Li, Mingshun ; Ajani, Jaffer A

    Publisher

    England: Elsevier Ltd

    Journal title

    The Lancet (British edition), 2021, Vol.398 (10294), p.27-40

    Record Identifier

    TN_cdi_proquest_journals_2547491434

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    5-Fluorouracil Adenocarcinoma Adenocarcinoma - drug therapy Adverse events Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Apoptosis Cancer Cancer therapies Cell death Chemotherapy Consent Diarrhea Drug Therapy, Combination Epidermal growth factor ErbB-2 protein Esophageal cancer Esophageal Neoplasms - drug therapy Esophagogastric Junction Esophagus Fatalities Female Growth factors Humans Immune Checkpoint Inhibitors - administration & dosage Immunotherapy Inhibitors Ligands Male Metastases Metastasis Middle Aged Monoclonal antibodies Movement disorders Nausea Nivolumab - administration & dosage Oncology Oxaliplatin Patients PD-1 protein PD-L1 protein Peripheral neuropathy Progression-Free Survival Safety Stomach cancer Stomach Neoplasms - drug therapy Survival Targeted cancer therapy Tumors

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2547491434

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2547491434

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections